Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant by Ishani Landry, Jagadeesh Aluri, Nancy Hall, Dinesh Kumar, Satish Dayal, Margaret Moline, Larisa Reyderman

Connect to this object online.

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant by Satish Dayal, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Margaret Moline, Larisa Reyderman, Ishani Landry

Connect to this object online.

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant by Ishani Landry, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Satish Dayal, Margaret Moline, Larisa Reyderman

Connect to this object online.

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease by Seiichi Hayato, Osamu Takenaka, Sree Harsha Sreerama Reddy, Ishani Landry, Larisa Reyderman, Akihiko Koyama, Chad Swanson, Sanae Yasuda, Ziad Hussein

Connect to this object online.

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease by Hugo Geerts, Mike Walker, Rachel Rose, Silke Bergeler, Piet H. van derGraaf, Edgar Schuck, Akihiko Koyama, Sanae Yasuda, Ziad Hussein, Larisa Reyderman, Chad Swanson, Antonio Cabal

Connect to this object online.